cNP8
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout cNP8
cNP8 is a phase 1 stage product being developed by United Therapeutics for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT06223009. Target conditions include Burns.
What happened to similar drugs?
3 of 6 similar drugs in Burns were approved
Approved (3) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06223009 | Phase 1 | Completed |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R-Pdf/Gbb 0.01% gel | Johnson & Johnson | Phase 2 | 31 |
| Ceftolozane/tazobactam | Merck | Approved | 35 |
| linezolid | Pfizer | Phase 1 | 29 |
| Somatropin + 0.09% Saline Solution | Pfizer | Phase 2/3 | 38 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 37 |
| cP12 | United Therapeutics | Phase 2 | 39 |
| Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications | Viatris | Approved | 32 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 29 |
| I-020502 | Baxter | Phase 2 | 32 |
| Pathogen-Reduced Plasma + Crystalloid Solutions | Cerus | Approved | 25 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 30 |
| NexoBrid | MediWound | Phase 3 | 30 |